Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 5/20 | 0.46 |
| ▸ | KDM5A | P29375 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GABRP | O00591 | 2/20 | 0.43 |
| ▸ | GABRD | O14764 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.43 |
| ▸ | GABRE | P78334 | 2/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.43 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4954467 | 0.83 | LMNA (0.50) | KDM5BKDM5ALMNASMN1; SMN2GABRP | |
| SCHEMBL23674956 | 0.79 | KAT8 (0.44) | KDM5BKDM5ASMN1; SMN2GABRPGABRD | |
| SCHEMBL11036114 | 0.78 | GABRP (0.47) | KDM5BKDM5ASMN1; SMN2GABRPGABRD | |
| SCHEMBL649610 | 0.78 | AGTR1 (0.42) | KDM5BKDM5ALMNASMN1; SMN2GABRP | |
| SCHEMBL28382 | 0.77 | GABRP (0.54) | LMNAGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL28523217 | 0.77 | NOS2 (0.49) | KDM5BKDM5AGABRPGABRDGABRA1 | |
| SCHEMBL19305015 | 0.77 | SMN1; SMN2 (0.50) | KDM5BKDM5ALMNASMN1; SMN2KDM4E | |
| SCHEMBL28129531 | 0.76 | NOS2 (0.50) | LMNASMN1; SMN2KDM4EALDH1A1MEN1 | |
| SCHEMBL28972443 | 0.75 | ASPH (0.41) | KDM5BKDM5ALMNAGABRPGABRD | |
| SCHEMBL679426 | 0.74 | TSHR (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104411707-A | Substituted phenylimidazopyrazoles and their use | Bayer Pharma AG | 2015-03-11 | — | — | CN | disclosed |
| US-8703797-B2 | Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (S1P2) receptors | ALLERGAN, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130296361-A1 | Condensed Ring Pyridine Compounds As Subtype-Selective Modulators Of Sphingosine-1-Phosphate-2 (S1P2) Receptors | ALLERGAN, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8507682-B2 | Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (S1P2) receptors | ALLERGAN, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120208840-A1 | Condensed Ring Pyridine Compounds As Subtype-Selective Modulators Of Sphingosine-1-Phosphate-2 (S1P2) Receptors | ALLERGAN, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2483245-A1 | CONDENSED RING PYRIDINE COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-2 (S1P2) RECEPTORS | Allergan, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011041287-A1 | CONDENSED RING PYRIDINE COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-2 (S1P2) RECEPTORS | ALLERGAN, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296361-A1 | Condensed Ring Pyridine Compounds As Subtype-Selective Modulators Of Sphingosine-1-Phosphate-2 (S1P2) Receptors | S1PR1, S1PR2, S1PR3 | KDM5B 1614/4885KDM5A 2124/4885LMNA 1307/4885 |
| US-20120208840-A1 | Condensed Ring Pyridine Compounds As Subtype-Selective Modulators Of Sphingosine-1-Phosphate-2 (S1P2) Receptors | S1PR1, S1PR2, S1PR3 | KDM5B 1614/4885KDM5A 2124/4885LMNA 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.